The residual NADPH oxidase activity measured by flow cytometry (DHR probe) for patients AB1 and AB2 can explain the partial protection of these patients and the delay of the CGD diagnosis (Table 2). The gene discussed is FMO5; the disease is chronic granulomatous disease.